Abbott, St. Jude Announce $25B Merger Of Cardiovascular Medical Device Businesses
Under the agreement, St. Jude shareholders will receive $46.75 in cash and 0.8708 shares of Abbott common stock for each share of St. Jude stock.
The companies said that with St. Jude’s strong positions in heart failure devices, atrial fibrillation and cardiac rhythm management and Abbott’s “leading” positions in coronary intervention and transcatheter mitral valve repair, the combined company will hold No. 1...
To view the full article, register now.